GlassScriptPhysician profile
Robert Lewis Ikeman
NPI 1407831498
$17,444.05
in general payments reported to CMS, 2019-2025
31 companies · $810 in 2025
The $810 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,207 · 2020: $2,144 · 2021: $1,873 · 2022: $2,383 · 2023: $3,270 · 2024: $2,757 · 2025: $810.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,805 · Education: $31.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,805.40 |
| Education | $31.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,618.33 | 2019-2025 | |
| Amgen INC. | $2,515.18 | 2019-2025 | Krystexxa, Evenity, Enbrel |
| Novartis Pharmaceuticals Corporation | $1,935.59 | 2019-2025 | |
| Pfizer INC. | $1,358.71 | 2019-2024 | |
| Glaxosmithkline, LLC. | $955.97 | 2019-2025 | Benlysta |
| Lilly USA, LLC | $878.69 | 2019-2025 | Taltz, Zepbound |
| Astrazeneca Pharmaceuticals LP | $862.54 | 2021-2025 | Saphnelo, Evusheld |
| Ucb, INC. | $783.07 | 2019-2025 | Cimzia, Bimzelx |
| Janssen Biotech, INC. | $687.88 | 2019-2024 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $669.59 | 2019-2024 | Orencia |
| Horizon Therapeutics Plc | $534.39 | 2019-2023 | Krystexxa |
| Genzyme Corporation | $476.13 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $368.44 | 2019-2024 | Spevigo, Cyltezo, Ofev |
| Radius Health, INC. | $336.86 | 2019-2024 | Tymlos |
| Genentech USA, INC. | $233.87 | 2019-2025 | Actemra |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $174.68 | 2020-2024 | Tremfya |
| Celgene Corporation | $150.94 | 2019 | |
| Aurinia Pharma U.S., INC. | $135.14 | 2022-2023 | Lupkynis |
| Mallinckrodt Hospital Products INC. | $131.07 | 2020-2025 | Acthar |
| Fidia Pharma USA INC. | $120.88 | 2020-2023 | Hymovis, Triluron |
| Pacira Therapeutics, INC. | $112.05 | 2019-2021 | |
| Kiniksa Pharmaceuticals, LTD. | $65.62 | 2023 | Arcalyst |
| Alexion Pharmaceuticals, INC. | $63.95 | 2019-2022 | |
| Sobi, INC | $62.48 | 2019-2020 | |
| Kiniksa Pharmaceuticals International, Plc | $55.62 | 2024 | Arcalyst |
| Mallinckrodt Enterprises LLC | $46.61 | 2019 | |
| Mylan Institutional INC. | $32.51 | 2023 | |
| Fresenius Kabi USA, LLC | $26.28 | 2023 | Idacio |
| Oxford Immunotec USA INC | $18.55 | 2019 | |
| Almatica Pharma LLC | $17.65 | 2024 | Teriparatide |
| Ultragenyx Pharmaceutical INC. | $14.78 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Ikeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.